(MAGN) Magnera placeholder - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US55939A1079
Stock: Non-Woven, Medical Garments, Diapers, Wipes, Filtration
Total Rating 34
Risk 47
Buy Signal -0.14
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.5% |
| Relative Tail Risk | -9.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.19 |
| Alpha | -51.01 |
| Character TTM | |
|---|---|
| Beta | 1.616 |
| Beta Downside | 1.586 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.45% |
| CAGR/Max DD | -0.41 |
Description: MAGN Magnera placeholder January 25, 2026
Magnera Corporation (NYSE:MAGN) is a U.S.-based manufacturer of non-woven and related products that serves consumer-oriented end markets, notably healthcare and personal care. Its portfolio includes medical garments, wipes, dryer sheets, filtration media, baby diapers, adult incontinence products, tea bags, coffee filters, cable wrap, and other specialty components.
As of the latest Q4 2025 filing (released February 2026), Magnera reported revenue of approximately **$1.22 billion**, a **6 % year-over-year increase**, and an adjusted EPS of **$0.45**. The company’s operating margin expanded to **8.2 %**, driven by higher pricing power in medical-grade non-wovens and cost-saving initiatives in its filtration segment. The global non-woven market is projected to grow at a **~5 % CAGR through 2028**, with demand for healthcare-related textiles outpacing consumer segments due to an aging population and increased infection-control standards. Additionally, raw-material cost pressure has eased after a 2023-24 dip in petroleum-based polymer prices, which improves margin outlook for producers like Magnera.
For a deeper, data-rich analysis of Magnera’s valuation dynamics, you may find ValueRay’s platform useful as a next step.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -159.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.37 > 1.0 |
| NWC/Revenue: 25.66% < 20% (prev 24.69%; Δ 0.96% < -1%) |
| CFO/TA 0.03 > 3% & CFO 103.0m > Net Income -159.0m |
| Net Debt (1.71b) to EBITDA (125.0m): 13.68 < 3 |
| Current Ratio: 2.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.6m) vs 12m ago 1.84% < -2% |
| Gross Margin: 10.24% > 18% (prev 0.11%; Δ 1013 % > 0.5%) |
| Asset Turnover: 116.3% > 50% (prev 86.04%; Δ 30.25% > 0%) |
| Interest Coverage Ratio: -0.57 > 6 (EBITDA TTM 125.0m / Interest Expense TTM 143.0m) |
Altman Z'' 0.90
| A: 0.21 (Total Current Assets 1.42b - Total Current Liabilities 601.0m) / Total Assets 3.99b |
| B: -0.04 (Retained Earnings -159.0m / Total Assets 3.99b) |
| C: -0.03 (EBIT TTM -81.0m / Avg Total Assets 2.76b) |
| D: -0.12 (Book Value of Equity -353.0m / Total Liabilities 2.92b) |
| Altman-Z'' Score: 0.90 = B |
Beneish M -1.57
| DSRI: 1.23 (Receivables 522.0m/172.9m, Revenue 3.20b/1.31b) |
| GMI: 1.03 (GM 10.24% / 10.51%) |
| AQI: 1.45 (AQ_t 0.27 / AQ_t-1 0.19) |
| SGI: 2.45 (Revenue 3.20b / 1.31b) |
| TATA: -0.07 (NI -159.0m - CFO 103.0m) / TA 3.99b) |
| Beneish M-Score: -1.57 (Cap -4..+1) = CCC |
What is the price of MAGN shares?
As of February 10, 2026, the stock is trading at USD 14.58 with a total of 605,540 shares traded.
Over the past week, the price has changed by +9.05%, over one month by -0.68%, over three months by +62.00% and over the past year by -29.09%.
Over the past week, the price has changed by +9.05%, over one month by -0.68%, over three months by +62.00% and over the past year by -29.09%.
Is MAGN a buy, sell or hold?
Magnera placeholder has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold MAGN.
- StrongBuy: 0
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MAGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17 | 16.6% |
| Analysts Target Price | 17 | 16.6% |
| ValueRay Target Price | 10.2 | -29.8% |
MAGN Fundamental Data Overview February 08, 2026
P/S = 0.1606
P/B = 0.4972
Revenue TTM = 3.20b USD
EBIT TTM = -81.0m USD
EBITDA TTM = 125.0m USD
Long Term Debt = 1.99b USD (from longTermDebt, two quarters ago)
Short Term Debt = 18.0m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.71b USD (from netDebt column, last quarter)
Enterprise Value = 2.19b USD (480.6m + Debt 2.02b - CCE 305.0m)
Interest Coverage Ratio = -0.57 (Ebit TTM -81.0m / Interest Expense TTM 143.0m)
EV/FCF = 60.85x (Enterprise Value 2.19b / FCF TTM 36.0m)
FCF Yield = 1.64% (FCF TTM 36.0m / Enterprise Value 2.19b)
FCF Margin = 1.12% (FCF TTM 36.0m / Revenue TTM 3.20b)
Net Margin = -4.96% (Net Income TTM -159.0m / Revenue TTM 3.20b)
Gross Margin = 10.24% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 9.42% (prev 10.73%)
Tobins Q-Ratio = 0.55 (Enterprise Value 2.19b / Total Assets 3.99b)
Interest Expense / Debt = 2.03% (Interest Expense 41.0m / Debt 2.02b)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.0m (EBIT -81.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.37 (Total Current Assets 1.42b / Total Current Liabilities 601.0m)
Debt / Equity = 1.89 (Debt 2.02b / totalStockholderEquity, last quarter 1.06b)
Debt / EBITDA = 13.68 (Net Debt 1.71b / EBITDA 125.0m)
Debt / FCF = 47.50 (Net Debt 1.71b / FCF TTM 36.0m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.77% (Net Income -159.0m / Total Assets 3.99b)
RoE = -14.47% (Net Income TTM -159.0m / Total Stockholder Equity 1.10b)
RoCE = -2.62% (EBIT -81.0m / Capital Employed (Equity 1.10b + L.T.Debt 1.99b))
RoIC = -2.06% (negative operating profit) (NOPAT -64.0m / Invested Capital 3.11b)
WACC = 3.58% (E(480.6m)/V(2.50b) * Re(11.87%) + D(2.02b)/V(2.50b) * Rd(2.03%) * (1-Tc(0.21)))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 6.07%
[DCF Debug] Terminal Value 83.26% ; FCFF base≈36.0m ; Y1≈27.7m ; Y5≈17.4m
Fair Price DCF = N/A (negative equity: EV 539.1m - Net Debt 1.71b = -1.17b; debt exceeds intrinsic value)
EPS Correlation: -27.07 | EPS CAGR: 0.81% | SUE: -0.31 | # QB: 0
Revenue Correlation: 68.01 | Revenue CAGR: 25.24% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=-0.011 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=1.01 | Chg30d=-0.044 | Revisions Net=-1 | Growth EPS=+130.3% | Growth Revenue=+3.5%
EPS next Year (2027-09-30): EPS=1.54 | Chg30d=-0.045 | Revisions Net=-1 | Growth EPS=+53.3% | Growth Revenue=+2.3%
P/B = 0.4972
Revenue TTM = 3.20b USD
EBIT TTM = -81.0m USD
EBITDA TTM = 125.0m USD
Long Term Debt = 1.99b USD (from longTermDebt, two quarters ago)
Short Term Debt = 18.0m USD (from shortTermDebt, last quarter)
Debt = 2.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.71b USD (from netDebt column, last quarter)
Enterprise Value = 2.19b USD (480.6m + Debt 2.02b - CCE 305.0m)
Interest Coverage Ratio = -0.57 (Ebit TTM -81.0m / Interest Expense TTM 143.0m)
EV/FCF = 60.85x (Enterprise Value 2.19b / FCF TTM 36.0m)
FCF Yield = 1.64% (FCF TTM 36.0m / Enterprise Value 2.19b)
FCF Margin = 1.12% (FCF TTM 36.0m / Revenue TTM 3.20b)
Net Margin = -4.96% (Net Income TTM -159.0m / Revenue TTM 3.20b)
Gross Margin = 10.24% ((Revenue TTM 3.20b - Cost of Revenue TTM 2.88b) / Revenue TTM)
Gross Margin QoQ = 9.42% (prev 10.73%)
Tobins Q-Ratio = 0.55 (Enterprise Value 2.19b / Total Assets 3.99b)
Interest Expense / Debt = 2.03% (Interest Expense 41.0m / Debt 2.02b)
Taxrate = 21.0% (US default 21%)
NOPAT = -64.0m (EBIT -81.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.37 (Total Current Assets 1.42b / Total Current Liabilities 601.0m)
Debt / Equity = 1.89 (Debt 2.02b / totalStockholderEquity, last quarter 1.06b)
Debt / EBITDA = 13.68 (Net Debt 1.71b / EBITDA 125.0m)
Debt / FCF = 47.50 (Net Debt 1.71b / FCF TTM 36.0m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.77% (Net Income -159.0m / Total Assets 3.99b)
RoE = -14.47% (Net Income TTM -159.0m / Total Stockholder Equity 1.10b)
RoCE = -2.62% (EBIT -81.0m / Capital Employed (Equity 1.10b + L.T.Debt 1.99b))
RoIC = -2.06% (negative operating profit) (NOPAT -64.0m / Invested Capital 3.11b)
WACC = 3.58% (E(480.6m)/V(2.50b) * Re(11.87%) + D(2.02b)/V(2.50b) * Rd(2.03%) * (1-Tc(0.21)))
Discount Rate = 11.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 6.07%
[DCF Debug] Terminal Value 83.26% ; FCFF base≈36.0m ; Y1≈27.7m ; Y5≈17.4m
Fair Price DCF = N/A (negative equity: EV 539.1m - Net Debt 1.71b = -1.17b; debt exceeds intrinsic value)
EPS Correlation: -27.07 | EPS CAGR: 0.81% | SUE: -0.31 | # QB: 0
Revenue Correlation: 68.01 | Revenue CAGR: 25.24% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.20 | Chg30d=-0.011 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=1.01 | Chg30d=-0.044 | Revisions Net=-1 | Growth EPS=+130.3% | Growth Revenue=+3.5%
EPS next Year (2027-09-30): EPS=1.54 | Chg30d=-0.045 | Revisions Net=-1 | Growth EPS=+53.3% | Growth Revenue=+2.3%